###begin article-title 0
###xml 162 168 <span type="species:ncbi:9606">Humans</span>
Muscle-Derived Angiopoietin-Like Protein 4 Is Induced by Fatty Acids via Peroxisome Proliferator-Activated Receptor (PPAR)-delta and Is of Metabolic Relevance in Humans
###end article-title 0
###begin p 1
###xml 38 73 38 73 <email xmlns:xlink="http://www.w3.org/1999/xlink">harald.staiger@med.uni-tuebingen.de</email>
Corresponding author: Harald Staiger, harald.staiger@med.uni-tuebingen.de
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 173 178 <span type="species:ncbi:9606">human</span>
OBJECTIVE- Long-chain fatty acids (LCFAs) contribute to metabolic homeostasis in part via gene regulation. This study's objective was to identify novel LCFA target genes in human skeletal muscle cells (myotubes).
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 229 234 <span type="species:ncbi:9606">Human</span>
RESEARCH DESIGN AND METHODS- In vitro methods included culture and treatment of human myotubes and C2C12 cells, gene array analysis, real-time RT-PCR, Western blotting, ELISA, chromatin immunoprecipitation, and RNA interference. Human subjects (two cohorts) were characterized by oral glucose tolerance test, hyperinsulinemic-euglycemic clamp, magnetic resonance imaging and spectroscopy, and standard blood analyses (glucose, insulin, C-peptide, and plasma lipids).
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 367 372 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 385 390 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 414 421 398 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 494 501 474 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 567 571 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 673 680 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 826 827 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 868 869 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1004 1011 980 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1033 1034 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 697 702 <span type="species:ncbi:9606">human</span>
RESULTS- We show here that ANGPTL4 (encoding angiopoietin-like protein 4) represents a prominent LCFA-responsive gene in human myotubes. LCFA activated peroxisome proliferator-activated receptor (PPAR)-delta, but not PPAR-alpha or -gamma, and pharmacological activation of PPAR-delta markedly induced ANGPTL4 production and secretion. In C2C12 myocytes, knockdown of PPARD, but not of PPARG, blocked LCFA-mediated ANGPTL4 induction, and LCFA treatment resulted in PPAR-delta recruitment to the ANGPTL4 gene. In addition, pharmacological PPAR-delta activation induced LIPE (encoding hormone-sensitive lipase), and this response crucially depended on ANGPTL4, as revealed by ANGPTL4 knockdown. In a human cohort of 108 thoroughly phenotyped subjects, plasma ANGPTL4 positively correlated with fasting nonesterified fatty acids (P = 0.0036) and adipose tissue lipolysis (P = 0.0012). Moreover, in 38 myotube donors, plasma ANGPTL4 levels and adipose tissue lipolysis in vivo were reflected by basal myotube ANGPTL4 expression in vitro (P = 0.02, both).
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 151 157 <span type="species:ncbi:9606">humans</span>
CONCLUSIONS- ANGPTL4 is produced by human myotubes in response to LCFA via PPAR-delta, and muscle-derived ANGPTL4 seems to be of systemic relevance in humans.
###end p 6
###begin p 7
Published ahead of print at  on 15 December 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
The metabolic syndrome, a cluster of health problems including visceral obesity, subclinical inflammation, insulin resistance, and type 2 diabetes, is the prevailing metabolic disorder in Western industrialized countries. The syndrome is caused by environmental factors (high-caloric food intake, sedentary lifestyle) combined with a genetic predisposition. Elevated plasma nonesterified fatty acid (NEFA) levels are frequently observed in metabolic syndrome patients and result from increased lipolysis of insulin-resistant white adipose tissue (WAT) and/or chronically excessive dietary fat intake (1).
###end p 9
###begin p 10
###xml 366 367 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 419 420 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 457 458 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 503 504 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
Among the major plasma long-chain fatty acid (LCFA) species, the saturated fatty acids palmitate and stearate are of particular interest with respect to their potential involvement in metabolic disarrangements, such as hyperglycemia, hyperinsulinemia, hypertriglyceridemia, and beta-cell dysfunction: administered chronically, they reduce muscular glucose disposal (2), promote hepatic triglyceride and VLDL synthesis (3), impair hepatic insulin clearance (4), and inhibit pancreatic insulin secretion (5). One proposed mechanism underlying all these metabolic LCFA effects is ectopic lipid deposition in muscle, liver, and pancreatic islets. The molecular links between LCFA actions and ectopic lipid deposition are however not well understood.
###end p 10
###begin p 11
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 389 390 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 391 392 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 563 564 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 755 757 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 882 884 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 885 887 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1065 1067 1038 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 274 279 <span type="species:ncbi:9606">human</span>
###xml 522 527 <span type="species:ncbi:9606">human</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
Recent data suggest that saturated fatty acids exert direct gene regulatory effects and may also in this way contribute to metabolic syndrome (6). We reported that palmitate and stearate, via nuclear factor kappaB (NF-kappaB) activation, provoke an inflammatory response in human skeletal muscle (SKM) and coronary artery endothelial cells by induction of the gene encoding interleukin-6 (7,8). Very high concentrations of these LCFA species, again via NF-kappaB, induce pro-apoptotic genes and promote apoptotic death of human coronary artery endothelial cells (9). Furthermore, saturated fatty acids impair mitochondrial activity of SKM cells by repression of the gene encoding peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1beta (10), and reduced muscular oxidative capacity was clearly demonstrated in patients with insulin resistance and type 2 diabetes (11,12). By contrast, unsaturated fatty acids, such as palmitoleate, oleate, and linoleate, increase mitochondrial activity of SKM cells by induction of PPAR-gamma coactivator-1alpha (10).
###end p 11
###begin p 12
###xml 244 249 <span type="species:ncbi:9606">human</span>
Even though LCFA-regulated transcription factors (NF-kappaB, PPARs) are known to date, LCFA-dependent gene regulation and its involvement in metabolic disease is not yet well understood. Therefore, it was this study's objective to identify, in human SKM cells differentiated in vitro (myotubes), novel LCFA target genes that could represent potential candidate contributors to the metabolic syndrome.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
A detailed description of the methods is given in the online appendix (found at ).
###end p 14
###begin p 15
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 27 33 <span type="species:ncbi:10090">murine</span>
###xml 131 136 <span type="species:ncbi:9606">Human</span>
Primary human myotubes and murine C2C12 myocytes were used for cell experiments. Microarray analysis was performed with Affymetrix Human Genome U133 Plus 2.0 arrays. Real-time RT-PCR was performed with SYBR Green I dye on a LightCycler. The anti-ANGPTL4 antibody from BioVendor was used for immunoblotting. Intracellular and secreted ANGPTL4 was quantified by ELISA. For RNA interference (RNAi), siGENOME siRNA sets designed by Dharmacon were used. Chromatin immunoprecipitation (ChIP) analysis was performed with the anti-PPAR-delta antibody K-20 from Santa Cruz Biotechnology.
###end p 15
###begin p 16
All 38 myotube donors underwent an oral glucose tolerance test (OGTT) and a hyperinsulinemic-euglycemic clamp. The 108 subjects with plasma ANGPTL4 measurements were characterized by OGTT and a subgroup of 91 subjects also by hyperinsulinemic-euglycemic clamp. All subjects gave informed written consent to the study. The protocol was approved by the local ethics committee. Total, visceral, and nonvisceral fat was determined by magnetic resonance imaging. Intramyocellular and intrahepatic lipids were measured by magnetic resonance spectroscopy. Glucose, insulin, C-peptide, NEFA, glycerol, triglycerides, and ANGPTL4 were quantified by standard laboratory methods.
###end p 16
###begin title 17
RESULTS AND DISCUSSION
###end title 17
###begin title 18
Gene array analysis.
###end title 18
###begin p 19
###xml 648 655 648 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 960 967 960 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 969 976 969 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 161 167 <span type="species:ncbi:9913">bovine</span>
###xml 505 510 <span type="species:ncbi:9606">human</span>
In an initial attempt to identify novel LCFA target genes related to metabolic syndrome, we treated human myotubes derived from a healthy male German donor with bovine serum albumin (BSA; carrier control), the saturated fatty acid palmitate, or the unsaturated fatty acid linoleate and performed whole-genome gene array analysis. Palmitate treatment repressed 181 and induced 316 genes, and linoleate repressed 30 and induced 104 genes. Thus, LCFAs appear to influence the expression of numerous genes in human myotubes. Notably, only five genes were repressed (Supplementary Table 3, found in the online appendix), and only 35 genes were induced (Table 1) by both palmitate and linoleate. Thus, the majority of LCFA-regulated genes appear to represent LCFA-specific targets, and modulation of their expression might depend on LCFA chain length and/or the degree of saturation. The gene that revealed highest fold-induction by both palmitate and linoleate was ANGPTL4 (Table 1), encoding angiopoietin-like protein 4 (ANGPTL4). The sole purpose of this single nonreplicated experiment was to generate new hypotheses. Therefore, these results cannot be generalized.
###end p 19
###begin p 20
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 168 170 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 293 295 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 625 627 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 628 630 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 680 682 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 739 741 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 742 744 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 827 829 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 830 832 826 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 848 854 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANPTL4</italic>
###xml 957 959 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 968 975 964 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
###xml 912 917 <span type="species:ncbi:10090">mouse</span>
ANGPTL4 was described as hepatic fibrinogen/angiopoietin-related protein (13), fasting-induced adipose factor (14), and PPAR-gamma target gene related to angiopoietin (15) and was characterized as a secreted protein predominantly produced by WAT, but also at lower levels by other tissues (13-15). The role of ANGPTL4 was extensively explored in mice by injection, targeted gene knockout, and transgenic and retroviral overexpression, and in this way, ANGPTL4 was shown to affect lipid metabolism: by inhibition of lipoprotein lipase (LPL), clearance of VLDL and chylomicrons is blocked and hypertriglyceridemia is provoked (16-20). Furthermore, ANGPTL4 stimulates WAT lipolysis (21) resulting in elevated plasma glycerol and NEFA levels (16,21). Besides hyperlipidemia, ANGPTL4 promotes WAT weight loss and hepatic steatosis (18,21). Importantly, ANPTL4 expression was consistently found upregulated in genetic mouse models of obesity and type 2 diabetes (15). Thus, ANGPTL4 represents a metabolically relevant candidate gene induced by common plasma LCFA species.
###end p 20
###begin title 21
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human myotube ANGPTL4 expression before and after LCFA treatment.
###end title 21
###begin p 22
###xml 94 101 94 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 190 197 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 231 232 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 334 341 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 450 457 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 495 502 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 310 315 <span type="species:ncbi:9606">human</span>
To assess whether ANGPTL4 is produced by human myotubes at relevant levels, we measured basal ANGPTL4 mRNA expression by real-time RT-PCR. Untreated human myotubes expressed 20.9 +/- 7.2 fg ANGPTL4 mRNA/mug total RNA (mean +/- SD; n = 5). This level was not only in the range of that found in a representative human SKM biopsy (12 fg ANGPTL4 mRNA/mug total RNA) but also represents approximately40% of the mRNA level found in subcutaneous WAT (56 fg ANGPTL4 mRNA/mug total RNA), a major site of ANGPTL4 expression.
###end p 22
###begin p 23
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 222 229 222 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 290 297 290 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 362 369 362 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 376 383 376 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 586 593 586 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 600 607 600 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 903 910 903 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 933 940 933 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1426 1427 1426 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1420 1427 1420 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 1898 1905 1898 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 2123 2130 2123 2130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 2143 2144 2143 2144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2159 2160 2159 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 1884 1889 <span type="species:ncbi:9606">human</span>
To confirm the gene array results and to explore the influence of other plasma LCFAs on ANGPTL4 expression, we treated human myotubes with BSA or selected major plasma LCFA species and subsequently quantified the cellular ANGPTL4 mRNA contents by real-time RT-PCR (normalized to 28S rRNA). ANGPTL4 mRNA expression was induced 10- to 50-fold by all LCFAs tested (Fig. 1A). The ANGPTL4 mRNA levels found after treatment with palmitate, stearate, palmitoleate, oleate, linoleate, or a combination of palmitate and linoleate were significantly different from their respective BSA controls (Fig. 1A). The ANGPTL4 mRNA contents detected after treatment with a combination of palmitate and linoleate did not significantly differ from those obtained with palmitate or linoleate alone. Thus, treatment with palmitate or linoleate alone might already be sufficient to reach the maximum response of LCFA-inducible ANGPTL4 expression. Moreover, ANGPTL4 induction depended neither on the chain length nor on the saturated/unsaturated nature of the LCFA but, rather, represented a general LCFA effect. To verify these LCFA-mediated gene regulations at the protein level, we used the first commercially available ELISA kit and measured intracellular ANGPTL4 contents after 20 h LCFA treatment. All LCFAs increased intracellular ANGPTL4 protein 1.5- to 2.3-fold, with palmitate, oleate, and linoleate reaching statistical significance (Fig. 1B). The observed differences between mRNA and protein induction rates are a well-known phenomenon that most probably reflects that gene transcription rate and mRNA half-life are not necessarily tightly linked to translation efficiency and protein half-life. In addition, we tried to measure and visualize secreted ANGPTL4 protein. However, the high BSA concentrations used for LCFA treatment interfered with the detection of secreted ANGPTL4. To see whether human myotube ANGPTL4 expression was modulated by glucose, we performed a dose-response experiment with 2.5, 5, 10, and 25 mmol/l glucose (added to glucose-free medium). After 20 h, there was no significant glucose effect on basal myotube ANGPTL4 expression (P = 0.9, ANOVA; n = 4).
###end p 23
###begin p 24
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
Because ANGPTL4 was described as a fasting-induced factor (14,15,22) and plasma LCFAs are known to be elevated during the fasting state due to unsuppressed WAT lipolysis, these results turn plasma LCFAs into potential candidate mediators of fasting-induced ANGPTL4 production.
###end p 24
###begin title 25
###xml 14 19 <span type="species:ncbi:9606">human</span>
Modulation of human myotube PPAR isoform expression and activation by LCFAs.
###end title 25
###begin p 26
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 66 68 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 69 71 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 96 98 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 99 101 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 166 173 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 180 182 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 222 229 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 308 313 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARA</italic>
###xml 315 320 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 325 330 301 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 454 459 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 521 526 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARA</italic>
###xml 531 536 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 563 568 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARA</italic>
###xml 573 578 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 688 689 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 712 713 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 765 772 727 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 780 781 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 774 781 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 798 803 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 860 865 822 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 890 891 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 918 919 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 928 929 890 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1021 1028 983 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1277 1278 1235 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 434 439 <span type="species:ncbi:9606">human</span>
ANGPTL4 is a known target gene of PPAR-alpha and -delta in liver (14,22) and PPAR-gamma in WAT (14,15), and a PPAR response element was identified in intron 3 of the ANGPTL4 gene (23). To see whether LCFAs enhance myotube ANGPTL4 expression via induction of the genes encoding PPAR-alpha, -gamma, or -delta (PPARA, PPARG, or PPARD, respectively), we quantified the respective mRNA levels before and after LCFA treatment. In untreated human myotubes, the PPARD mRNA contents were approximately10-fold higher than those of PPARA and PPARG (data not shown). Neither PPARA nor PPARG mRNA contents were significantly altered by LCFA treatment when compared with their respective BSA controls (P >/= 0.2, both, ANOVA; n = 5). Furthermore, all LCFAs shown above to induce ANGPTL4 (Fig. 1A) did not induce PPARD expression, with only one exception: stearate increased PPARD mRNA contents 2.6-fold (P < 0.0001, ANOVA; post hoc P < 0.05; n = 5). This stearate-specific effect, however, cannot explain the general effect of LCFA on ANGPTL4 expression. To explore whether stearate's inductive effect is translated to the protein level, we performed immunoblot analysis. None of the LCFAs tested, including stearate, provoked relevant changes in PPAR-delta protein after 20 h of treatment (n = 3; data not shown). Therefore, we suggest that LCFAs act as PPAR ligands or activators (intracellularly metabolized to ligands), but not as regulators of PPAR expression/production.
###end p 26
###begin p 27
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 245 247 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 250 254 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD36</italic>
###xml 293 297 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3</italic>
###xml 362 364 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 365 367 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 374 379 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 414 416 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 510 514 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD36</italic>
###xml 516 520 500 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UCP3</italic>
###xml 525 530 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 547 548 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 570 571 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 610 614 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 794 795 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 788 795 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 891 896 <span type="species:ncbi:9606">human</span>
To examine whether LCFAs are able to activate one of the three PPAR isoforms in human myotubes, we also quantified the mRNA levels of PPAR target genes, i.e., PDK4 (encoding pyruvate dehydrogenase kinase 4) as a target of PPAR-delta and -alpha (24), CD36 (encoding fatty acid translocase) and UCP3 (encoding uncoupling protein 3) as PPAR-alpha-specific targets (25,26), and PPARG as a target of PPAR-gamma itself (27). Compared with their respective BSA controls, none of the LCFAs modulated the expression of CD36, UCP3, or PPARG in these cells (P >/= 0.4, all, ANOVA; n >/= 4). By contrast, all LCFA induced PDK4 mRNA expression 7- to 22-fold, and the effects of palmitate, palmitoleate, oleate, linoleate, and the combination of palmitate and linoleate were statistically significant (Fig. 1C). This led us to assume that the LCFAs tested in this study selectively activate PPAR-delta in human myotubes, at least at the concentration tested (0.5 mmol/l).
###end p 27
###begin title 28
###xml 15 20 <span type="species:ncbi:9606">human</span>
Stimulation of human myotube ANGPTL4 production by pharmacological PPAR activation.
###end title 28
###begin p 29
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 317 318 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 311 318 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 320 327 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 465 472 453 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 688 695 672 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 756 763 740 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 849 853 829 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 862 863 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 855 863 835 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Figs. 2<italic>B</italic></xref>
###xml 869 870 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 868 870 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">2<italic>C</italic></xref>
###xml 1108 1109 1083 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1120 1121 1095 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1128 1129 1103 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1230 1237 1201 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 1252 1257 <span type="species:ncbi:9606">human</span>
To further investigate the role of PPAR isoforms in human myotube ANGPTL4 expression, we treated the cells with the PPAR-alpha-specific fibrates Wy-14,643 and fenofibrate, the PPAR-gamma-specific thiazolidinediones troglitazone and rosiglitazone, and the PPAR-delta-specific activator GW501516. As presented in Fig. 2A, ANGPTL4 mRNA expression was markedly induced by GW501516 and moderately induced by troglitazone (17-fold and 4-fold, respectively). By contrast, ANGPTL4 mRNA expression was neither altered by rosiglitazone, a thiazolidinedione with 10-fold higher affinity for PPAR-gamma than troglitazone, nor by any of the fibrates tested. Only GW501516 treatment reached a level of ANGPTL4 induction comparable to that found with LCFAs. Furthermore, ANGPTL4 induction by GW501516 followed the same kinetics as the other PPAR-delta target gene PDK4 (Figs. 2B and 2C). We also tested GW501516's effect on intracellular ANGPTL4 protein contents using ELISA. GW501516 treatment (1 mumol/l, 20 h) increased intracellular ANGPTL4 protein 2.5-fold over DMSO control (365.6 +/- 52.9 vs. 908.2 +/- 154.0 pg/mg; P = 0.0158, t test; n = 4). These data strengthened our suggestion of PPAR-delta being a crucial mediator of LCFA-induced ANGPTL4 expression in human myotubes.
###end p 29
###begin p 30
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 143 150 143 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 459 460 447 448 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 558 560 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 561 563 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 564 566 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 857 858 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 851 858 839 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic></xref>
###xml 867 868 855 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 988 989 976 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 160 165 <span type="species:ncbi:9606">human</span>
###xml 655 660 <span type="species:ncbi:9606">human</span>
###xml 1091 1096 <span type="species:ncbi:9606">human</span>
In addition, 48-h treatment of human myotubes with GW501516 resulted in continuous accumulation of ANGPTL4 protein in the culture supernatant (Fig. 2D). Hence, human ANGPTL4 can be added to the novel and growing list of muscle-derived secreted proteins with metabolic functions (myokines), which also comprises interleukin-6 (28), interleukin-15 (29), and musclin (30). Besides full-length ANGPTL4 (approximately70 kDa), a 50-kDa COOH-terminal and a 26-kDa NH2-terminal fragment (both with biological activity) were reported to circulate in the bloodstream (18,23,31). Therefore, we asked whether ANGPTL4 secreted into the supernatant by GW501516-treated human myotubes is proteolytically cleaved. Immunoblotting revealed that both full-length ANGPTL4 and the COOH-terminal fragment accumulated in the culture supernatant during the treatment period (Fig. 2E). The NH2-terminal fragment could not be detected with antibodies from different suppliers directed against full-length or the NH2-terminal part of ANGPTL4 and, thus, seems to be rapidly degraded. In conclusion, ANGPTL4 secreted by human myotubes is cleaved and biologically activated.
###end p 30
###begin title 31
###xml 36 43 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
Role of PPAR-delta in LCFA-enhanced ANGPTL4 expression in C2C12 myocytes.
###end title 31
###begin p 32
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 96 101 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 354 355 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 348 355 344 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 394 401 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 571 578 567 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 732 739 728 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 792 793 788 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 786 793 782 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 817 818 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 811 818 807 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 861 866 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 948 953 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 982 987 978 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1014 1021 1010 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1117 1122 1113 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1192 1193 1188 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1186 1193 1182 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 1300 1307 1296 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1335 1336 1331 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1329 1336 1325 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 1358 1365 1354 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1469 1474 1461 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARA</italic>
###xml 1642 1647 1634 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARA</italic>
###xml 1716 1723 1708 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1790 1795 1782 1787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1839 1844 1831 1836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARG</italic>
###xml 1935 1942 1927 1934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1955 1956 1947 1948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1964 1965 1956 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1972 1973 1964 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2003 2010 1995 2002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 139 145 <span type="species:ncbi:10090">murine</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 651 657 <span type="species:ncbi:10090">murine</span>
###xml 689 694 <span type="species:ncbi:9606">human</span>
To evidence that LCFA-induced myocyte ANGPTL4 expression depends on PPAR-delta, we knocked down PPARD expression by RNAi. This was done in murine C2C12 myocytes because human myotubes could not be efficiently transfected. First, we treated C2C12 myocytes with representative saturated fatty acid and unsaturated fatty acid species. As presented in Fig. 3A, all LCFAs tested increased the C2C12 ANGPTL4 mRNA contents when compared with their respective BSA controls, and the effects of stearate, oleate, and linoleate reached the level of significance. Thus, LCFA-induced ANGPTL4 expression was not restricted to human myotubes but was reproduced in a murine SKM cell line. Moreover, as in human myotubes, GW501516 treatment induced ANGPTL4 mRNA expression up to 20-fold in C2C12 cells (Fig. 3B). As depicted in Fig. 3C, transfection with siRNA directed against PPARD, but not with control siRNA directed against bacterial luciferase, reduced C2C12 PPARD mRNA contents by 82%. After PPARD knockdown, oleate-induced ANGPTL4 expression was significantly impaired (2.4-fold in the presence vs. 6.8-fold in the absence of PPARD siRNA); moreover, the oleate effect was no longer significant (Fig. 3D). Furthermore, control transfection with siRNA directed against bacterial luciferase still allowed marked ANGPTL4 induction by oleate (Fig. 3D). Thus, induction of ANGPTL4 expression in C2C12 myocytes by the representative LCFA oleate requires PPAR-delta. Importantly, C2C12 PPARA expression ranged at the detection limit of the real-time PCR method, even upon utilization of sensitivity-enhancing hybridization probes. Therefore, we conclude that PPARA is not expressed in these cells and is not involved in LCFA-induced ANGPTL4 expression. Transfection of the cells with siRNA directed against PPARG, but not with control siRNA, reduced C2C12 PPARG expression by 88%. However, this manipulation had no significant impact on oleate-induced ANGPTL4 expression (P = 1.0, t test; n = 3). Hence, LCFA effects on ANGPTL4 expression are specifically mediated by PPAR-delta.
###end p 32
###begin p 33
###xml 75 82 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 216 223 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 339 340 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 333 340 325 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>E</italic></xref>
###xml 423 430 411 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
To ultimately prove that PPAR-delta is activated by LCFAs and binds to the ANGPTL4 gene, we performed ChIP analysis in C2C12 cells treated for 6 h with oleate. In the anti-PPAR-delta immunoprecipitate, markedly more ANGPTL4 intron 2 DNA (harboring the PPRE) could be detected in oleate-treated cells compared with BSA-treated cells (Fig. 3E). This demonstrates that PPAR-delta is activated and recruited to the PPRE of the ANGPTL4 gene upon LCFA treatment.
###end p 33
###begin title 34
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
Effect of pharmacological ANGPTL4 induction on the expression of C2C12 myocyte lipases.
###end title 34
###begin p 35
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 343 349 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNPLA2</italic>
###xml 414 418 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 489 490 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 581 585 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 590 596 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNPLA2</italic>
###xml 609 610 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 615 616 608 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 603 616 596 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic> and <italic>B</italic></xref>
###xml 784 788 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 793 800 782 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 863 864 852 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 857 870 846 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic> and C</xref>
###xml 882 883 871 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 888 889 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 876 889 865 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic> and <italic>B</italic></xref>
###xml 911 915 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 920 926 909 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNPLA2</italic>
ANGPTL4 is reported to enhance WAT lipolysis via induction of adipose triglyceride lipase (21). We therefore asked whether triglyceride lipases of SKM cells, which are required for breakdown of intramyocellular triglycerides, are also under the control of muscle-derived ANGPTL4 (mANGPTL4). Untreated C2C12 myocytes expressed 46.3 +/- 10.6 fg PNPLA2 mRNA (encoding adipose triglyceride lipase) and 11.8 +/- 2.0 fg LIPE mRNA (encoding hormone-sensitive lipase)/mug total RNA (means +/- SD; n = 3). Treatment of C2C12 cells with GW501516 provoked significant increments over time of LIPE and PNPLA2 mRNA (Fig. 4A and B) compared with DMSO (carrier control). However, the kinetics of both gene regulations was completely different from that of the aforementioned PPAR-delta target genes PDK4 and ANGPTL4 in that these lipases showed delayed induction (compare Fig. 2B and C with Fig. 4A and B). This suggests that LIPE and PNPLA2 are not direct PPAR-delta target genes.
###end p 35
###begin p 36
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNPLA2</italic>
###xml 271 278 271 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 384 391 384 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 434 441 434 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 538 545 538 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 572 579 572 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 631 635 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 703 710 703 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 785 786 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 779 786 779 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
###xml 900 904 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 923 924 923 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 917 924 917 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>D</italic></xref>
The GW501516 effect on PNPLA2 expression was only obvious at very late time points (beyond 24 h after start of treatment) when DMSO alone also revealed some gene regulatory effects. Using RNAi, we therefore assessed here the potential autocrine/paracrine role of myocyte ANGPTL4 expression during the moderately delayed stage of LIPE expression (at 20 h of treatment). As depicted in Fig. 4C, transfection with siRNA directed against ANGPTL4, but not with control siRNA directed against bacterial luciferase, reduced the GW501516-induced ANGPTL4 mRNA contents by 90%. The ANGPTL4 knockdown significantly impaired GW501516-mediated LIPE induction (1.6-fold in the presence vs. 2.6-fold in the absence of ANGPTL4 siRNA); in addition, the GW501516 effect was no longer significant (Fig. 4D). Again, control transfection with bacterial luciferase siRNA did not significantly alter the GW501516 effect on LIPE expression (Fig. 4D).
###end p 36
###begin p 37
###xml 69 73 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 191 195 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 386 388 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
Here, we show that pharmacological PPAR-delta activation upregulates LIPE expression in C2C12 SKM cells and provide preliminary evidence for a role of mANGPTL4 in this gene regulatory event. LIPE induction is supposed to enhance intramyocellular lipolysis and to increase endogenous fatty acyl-CoA, the preferred substrate of SKM oxidative metabolism stimulated by PPAR-delta agonists (32). Moreover, this finding could point to an autocrine/paracrine function of mANGPTL4 in SKM. To corroborate the role of mANGPTL4 in the breakdown of intramyocellular lipids, further studies, e.g., in muscle-specific PPAR-delta gain- and loss-of-function animal models, are clearly needed. Because C2C12 cells do not store measurable amounts of triglycerides (data not shown), other muscle cell models are required to study ANGPTL4's lipolytic effect at the cellular level.
###end p 37
###begin title 38
###xml 60 66 <span type="species:ncbi:9606">humans</span>
Relationship between plasma ANGPTL4 and metabolic traits in humans.
###end title 38
###begin p 39
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 197 203 <span type="species:ncbi:9606">humans</span>
###xml 284 296 <span type="species:ncbi:9606">participants</span>
Because our in vitro data demonstrated a close relationship between ANGPTL4 and lipid metabolism, we assessed this protein's role in lipid metabolism, insulin sensitivity, and insulin secretion in humans in vivo. To this end, we quantified plasma ANGPTL4 in 108 thoroughly phenotyped participants of the Tuebingen Lifestyle Intervention Program (TULIP) (33-36), a cohort characterized by a wide range of age, BMI, body fat content, insulin sensitivity, and insulin secretion (clinical characteristics are presented in Supplementary Table 2) using ELISA.
###end p 39
###begin p 40
###xml 173 174 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 249 251 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 495 496 491 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 605 606 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 622 623 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 625 626 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 658 659 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 675 676 667 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 678 679 670 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 765 766 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 777 778 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 877 879 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 880 882 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1047 1048 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1132 1133 1122 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1255 1260 <span type="species:ncbi:9606">human</span>
The mean plasma ANGPTL4 concentration measured was 1.73 +/- 0.11 ng/ml (means +/- SE; range 0.37-8.00 ng/ml). The plasma ANGPTL4 levels were not correlated with sex or age (P = 0.9, both), and this is in good agreement with recently published data (37). There were no significant correlations with BMI; waist-to-hip ratio; body fat measured by bioelectrical impedance; total, visceral, and nonvisceral fat mass measured by magnetic resonance imaging; or plasma levels of adiponectin and leptin (P >/= 0.06, all, after appropriate adjustments). However, stratification of the cohort into lean (BMI <27 kg/m2, 19.5-26.9 kg/m2; n = 30) and obese (BMI >/=30 kg/m2, 30.0-48.4 kg/m2; n = 39) subjects revealed significantly elevated ANGPTL4 levels in the obese subgroup (P = 0.0172, t test). Thus, plasma ANGPTL4 is influenced by body adiposity reflecting ANGPTL4 production by WAT (13-15). Ectopic (intrahepatic and intramyocellular) lipids measured by magnetic resonance spectroscopy were neither associated with plasma ANGPTL4 in the overall cohort (P >/= 0.6, all; adjusted for sex, age, and BMI) nor in the lean and obese subgroups (P >/= 0.07, all; adjusted for sex and age). Thus, circulating ANGPTL4 does not appear to be involved in lipid breakdown in human muscle. This, however, does not exclude a role of locally produced mANGPTL4 in muscle lipolysis.
###end p 40
###begin p 41
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 510 511 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 653 654 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 750 751 746 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 883 885 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 886 888 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 999 1006 993 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1181 1183 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1173 1179 <span type="species:ncbi:9606">humans</span>
As to metabolic traits, plasma ANGPTL4 levels did not reveal significant associations with plasma glucose or insulin concentrations (in the fasting state as well as during OGTT), with OGTT- and hyperinsulinemic-euglycemic clamp-derived indexes of insulin sensitivity, or with indexes of insulin secretion, such as plasma C-peptide levels at 30 min of OGTT and OGTT-derived first-phase insulin secretion in the overall cohort (P >/= 0.24, all, after appropriate adjustments) or in the lean and obese subgroups (P >/= 0.3, all, after appropriate adjustments). Plasma triglyceride concentrations were also not significantly associated with ANGPTL4 before (P = 0.14; adjusted for sex, age, and BMI) and after stratification into lean and obese subjects (P >/= 0.3, all; adjusted for sex and age). Hence, the hypertriglyceridemic action of ANGPTL4 detected in mice due to LPL inhibition (16-20) could not be confirmed in this study. However, a very recent genetic study identified a rare mutation in the ANGPTL4 gene, E40K, in European Americans, which was associated with lower plasma triglyceride levels clearly pointing to a role of ANGPTL4 in VLDL/chylomicron metabolism in humans (38).
###end p 41
###begin p 42
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 102 109 102 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 263 264 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 257 264 257 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 451 457 <span type="species:ncbi:9606">humans</span>
###xml 500 504 <span type="species:ncbi:10090">mice</span>
Importantly, plasma ANGPTL4 levels were positively associated with plasma NEFAs in the fasting state (Fig. 5A), possibly reflecting NEFA-mediated ANGPTL4 production. In addition, plasma ANGPTL4 was positively correlated with plasma NEFA levels during OGTT (Fig. 5B), an estimate of WAT lipolysis. Even though these associations cannot constitute causality, these results clearly point to a close relationship between plasma NEFA and ANGPTL4 levels in humans and, in part, confirm earlier findings in mice.
###end p 42
###begin title 43
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
Relationship between myotube ANGPTL4 expression and metabolic traits of the donors.
###end title 43
###begin p 44
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 807 809 807 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 629 634 <span type="species:ncbi:9606">human</span>
The human myotubes used in this study underwent an extended cell culture protocol including isolation from biopsies, expansion, splitting and freezing, storage in liquid nitrogen and thawing, growth to subconfluence, and finally in vitro differentiation. As a result, these cells no longer reflect the metabolic setting in vivo and have lost acquired phenotypes, such as insulin resistance (39). However, some genetically or epigenetically determined features, e.g., susceptibility toward saturated fatty acids (40) and basal expression of genes (41,42), are maintained and show remarkable inter-individual variation. Therefore, human myotubes represent a model to study the unidirectional effects of genes and their individual expression levels on metabolic parameters of the donors, as discussed earlier (42).
###end p 44
###begin p 45
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 317 324 317 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 386 391 386 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 404 411 404 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>C</italic></xref>
###xml 44 50 <span type="species:ncbi:9606">humans</span>
To assess the metabolic role of mANGPTL4 in humans in vivo, we determined basal ANGPTL4 mRNA expression in myotubes from 38 nondiabetic donors (for clinical characteristics, see Staiger et al. [41]). From these subjects, plasma glycerol measurements were available in addition to plasma NEFAs. In the myotubes, basal ANGPTL4 expression revealed a strong positive correlation with basal PPARD expression (Fig. 5C) reflecting the close relationship between PPAR-delta and its target gene.
###end p 45
###begin p 46
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 134 135 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 434 435 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 824 831 820 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 844 845 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 945 952 939 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1068 1069 1062 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1062 1069 1056 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 1238 1244 <span type="species:ncbi:9606">humans</span>
By correlational analysis with the donors' in vivo parameters, the myotube ANGPTL4 mRNA contents were not associated with sex or age (P >/= 0.5, both). Furthermore, there were no significant correlations with BMI, waist-to-hip ratio, body fat content, plasma adiponectin and leptin levels, plasma glucose or insulin concentrations (in the fasting state as well as during OGTT), or indexes of insulin sensitivity or insulin secretion (P >/= 0.10, all, after appropriate adjustments). Intramyocellular lipid measurements were not available from the donors. Therefore, we have currently no proof of our in vitro finding suggesting involvement of mANGPTL4 in muscle triglyceride breakdown. As to lipid parameters, plasma fasting concentrations of triglycerides, NEFA, and glycerol were not significantly associated with myotube ANGPTL4 expression (P >/= 0.06, all; adjusted for sex, age, and BMI). However, a significant correlation between myotube ANGPTL4 expression and the area under the curve of glycerol during OGTT, an estimate of WAT lipolysis, was detected (Fig. 5D). This not only confirms the results obtained with plasma ANGPTL4 measurements but also indicates that mANGPTL4 is of systemic importance and enhances WAT lipolysis in humans.
###end p 46
###begin p 47
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 342 348 <span type="species:ncbi:9606">humans</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
To further substantiate the systemic role of mANGPTL4, we additionally measured the plasma ANGPTL4 concentrations of the myotube donors. Importantly, myotube ANGPTL4 expression was significantly correlated with the donors' plasma ANGPTL4 levels (Fig. 5E). This provides evidence that mANGPTL4 production contributes to circulating ANGPTL4 in humans. The myotube cultures were derived from normal-weight healthy young subjects. Thus, the interesting issue of whether myotubes from patients with metabolic disease (obesity, type 2 diabetes) show altered expression/secretion of ANGPTL4 remains to be clarified, and future studies will shed further light on this question.
###end p 47
###begin p 48
###xml 227 234 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 386 391 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 421 423 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 439 441 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 442 444 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 693 699 678 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6</xref>
###xml 1045 1050 1026 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1075 1077 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 1078 1080 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 1081 1083 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1222 1226 1203 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 1563 1569 1533 1539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 1069 1073 <span type="species:ncbi:10090">mice</span>
###xml 1671 1677 <span type="species:ncbi:9606">humans</span>
In summary, we show here that ANGPTL4 is produced and secreted by human myotubes and is subject to gene regulation by major plasma LCFAs. Furthermore, we provide evidence for an involvement of PPAR-delta in LCFA-induced muscle ANGPTL4 expression. These findings could be of physiological relevance in states of increased beta-oxidation due to enhanced muscle PPAR-delta activity and/or PPARD expression, such as fasting (43) and exercise (44-46). In this context, it is conceivable that promotion of WAT lipolysis via PPAR-delta-mediated mANGPTL4 production represents a mechanism that prevents too strong decrements of plasma NEFA levels and, in this way, ensures ongoing fuel supply of SKM (Fig. 6). Such a feed-forward mechanism would favor the efficient use of stored lipids, as opposed to glucose, during periods of increased energy demand. In this scenario, mANGPTL4 would be an important player of crosstalk between SKM and WAT and would explain the loss of WAT mass observed after pharmacological PPAR-delta activation and/or transgenic PPARD overexpression in mice (44,47,48). Clearly, further studies are needed to confirm this hypothesis. If our preliminary in vitro finding that mANGPTL4 is involved in muscle LIPE expression holds also for the in vivo situation, a synergism of PPAR-delta actions can be derived in which PPAR-delta activation, in an ANGPTL4-dependent manner, stimulates breakdown of intramyocellular lipids to fatty acyl-CoA and, in an ANGPTL4-independent manner, promotes acyl-CoA oxidation via induction of beta-oxidative enzymes (Fig. 6). Finally, this is to our knowledge the first report demonstrating systemic relevance of mANGPTL4 in humans.
###end p 48
###begin title 49
Supplementary Material
###end title 49
###begin title 50
Online-Only Appendix
###end title 50
###begin p 51
This study was supported by the German Research Foundation (KFO 114/1-2) and the European Community (EUGENE2, LSHM-CT-2004-512013).
###end p 51
###begin p 52
No potential conflicts of interest relevant to this article were reported.
###end p 52
###begin p 53
###xml 19 31 <span type="species:ncbi:9606">participants</span>
We thank all study participants for their cooperation and acknowledge the excellent technical assistance of Anna Bury, Heike Luz, and Alke Guirguis.
###end p 53
###begin title 54
REFERENCES
###end title 54
###begin p 55
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 275 276 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 313 320 313 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 420 421 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 556 557 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 568 569 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 674 675 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 735 736 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 22 27 <span type="species:ncbi:9606">human</span>
ANGPTL4 production by human myotubes and its regulation by LCFAs. Cells were treated for 20 h with 1.25% BSA (control for myristate, palmitate, palmitoleate, oleate, and linoleate), 2.5% BSA (control for stearate and palmitate + linoleate), or 0.5 mmol/l of each LCFA. A and C: Induction of the PPAR target genes ANGPTL4 (A) and PDK4 (C) by LCFA. RNA was quantified by real-time RT-PCR (relative arbitrary units [RAU]). B: Intracellular ANGPTL4 protein levels. ANGPTL4 protein was measured by ELISA and normalized to cellular protein contents. Statistics: P = 0.0008 (A), P = 0.0133 (B), and P < 0.0001 (C); ANOVA; n >/= 4; *significantly different from 1.25% BSA (post hoc P < 0.05); **significantly different from 2.5% BSA (post hoc P < 0.05).
###end p 55
###begin p 56
###xml 92 93 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 108 115 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 395 396 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 414 415 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 468 469 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 479 480 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 485 486 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 516 523 505 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 525 526 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 532 536 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDK4</italic>
###xml 538 539 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 733 734 721 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 745 746 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 752 753 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 764 765 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 799 800 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 806 807 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1080 1081 1067 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1123 1124 1110 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1130 1131 1117 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 1270 1275 <span type="species:ncbi:9606">human</span>
Induction of ANGPTL4 production in human myotubes by pharmacological PPAR-delta activation. A: Induction of ANGPTL4 expression by isoform-specific PPAR agonists. Cells were treated for 20 h with 0.1% DMSO (carrier control), 10 mumol/l Wy-14,643, 60 mumol/l fenofibrate, 10 mumol/l troglitazone, 1 mumol/l rosiglitazone, or 1 mumol/l GW501516. RNA was quantified by real-time RT-PCR. Statistics: P < 0.0001; ANOVA; n >/= 4; *significantly different from DMSO (post hoc P < 0.05). B and C: Time-dependent induction of ANGPTL4 (B) and PDK4 (C) by GW501516. Cells were treated for 48 h with 0.1% DMSO or 1 mumol/l GW501516. RNA was quantified by real-time RT-PCR. Statistics: *significant differences between treatment groups over time: P < 0.0001 (B) and P = 0.0021 (C); time versus treatment; MANOVA; n = 3. D: Time-dependent stimulation of ANGPTL4 secretion by GW501516. Cells were treated for 48 h with 0.1% DMSO or 1 mumol/l GW501516. ANGPTL4 secreted into the culture supernatant was quantified by ELISA. Statistics: *significant differences between treatment groups over time: P < 0.0001; time versus treatment; MANOVA; n = 3. E: Cleavage of secreted ANGPTL4 during GW501516 treatment. Cells were treated for 48 h with 1 mumol/l GW501516. Supernatants conditioned by human myotube cultures derived from two donors were subjected to immunoblot analysis.
###end p 56
###begin p 57
###xml 35 42 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 73 74 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 96 103 92 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 292 293 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 311 312 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 368 369 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 429 430 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 440 441 436 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 471 478 467 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 671 672 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 714 715 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 721 722 716 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 743 748 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 893 898 888 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1046 1047 1041 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1065 1066 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1118 1119 1113 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1129 1130 1124 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1147 1154 1142 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1187 1192 1182 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1320 1325 1315 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 1517 1518 1512 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1536 1537 1531 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1587 1588 1582 1583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1662 1663 1657 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1673 1674 1668 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1724 1731 1715 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 1964 1970 1951 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANPTL4</italic>
Role of PPAR-delta in LCFA-induced ANGPTL4 expression in C2C12 myocytes. A: Regulation of C2C12 ANGPTL4 expression by LCFAs. Cells were treated for 20 h with 1.25% BSA, 2.5% BSA, or 0.5 mmol/l of each LCFA. RNA was quantified by real-time RT-PCR (relative arbitrary units [RAU]). Statistics: P = 0.0012; ANOVA; n = 3; *significantly different from 1.25% BSA (post hoc P < 0.05); **significantly different from 2.5% BSA (post hoc P < 0.05). B: Time-dependent induction of ANGPTL4 by GW501516. Cells were treated for 20 h with 0.1% DMSO or 1 mumol/l GW501516. RNA was quantified by real-time RT-PCR. Statistics: *significant differences between treatment groups over time: P < 0.0001; time versus treatment; MANOVA; n = 3. C: Knockdown of C2C12 PPARD expression by RNAi. Cells were left untreated (basal) or were treated for 8 h with siRNA directed against bacterial luciferase (for control) or PPARD, respectively. Cells were lysed after siRNA washout and incubation with fresh medium for 16 h. RNA was quantified by real-time RT-PCR. Statistics: P < 0.0001; ANOVA; n = 3; *significantly different from basal (post hoc P < 0.05). D: Oleate-induced ANGPTL4 expression of C2C12 cells after PPARD knockdown. Cells were left untreated or were treated for 8 h with siRNA directed against bacterial luciferase (for control) or PPARD, respectively. After siRNA washout and 16-h incubation with fresh medium, cells were treated for 20 h with 1.25% BSA or 0.5 mmol/l oleate. RNA was quantified by real-time RT-PCR. Statistics: P = 0.0217; ANOVA; n = 3; *significantly different from BSA (post hoc P < 0.05); **significantly different from oleate + control siRNA (post hoc P < 0.05). E: Oleate-induced recruitment of PPAR-delta to the ANGPTL4 gene. Cells were treated for 6 h with 1.25% BSA or 0.5 mmol/l oleate, respectively. After cross-linking with formaldehyde, cells were subjected to anti-PPAR-delta ChIP. The co-immunoprecipitated DNA was analyzed for the presence of ANPTL4 DNA using PCR amplification of a 310-bp fragment harboring the PPRE in intron 3.
###end p 57
###begin p 58
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PNPLA2</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 345 346 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 357 358 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 364 365 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 376 377 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 411 412 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 418 419 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 440 447 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 619 626 617 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 794 795 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 813 814 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 868 869 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 879 880 877 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 888 892 886 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
###xml 910 917 908 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 972 973 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1028 1029 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1047 1048 1045 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1099 1100 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1176 1177 1174 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
ANGPTL4-dependent LIPE expression in C2C12 myocytes. A and B: Time-dependent induction of C2C12 LIPE (A) and PNPLA2 (B) by GW501516. Cells were treated for 48 h with 0.1% DMSO or 1 mumol/l GW501516. RNA was quantified by real-time RT-PCR (relative arbitrary units [RAU]). Statistics: *significant differences between treatment groups over time: P = 0.0007 (A) and P = 0.0002 (B); time versus treatment; MANOVA; n = 3. C: Knockdown of C2C12 ANGPTL4 expression by RNAi. Cells were treated for 8 h with 1 mumol/l GW501516 alone (control) or with GW501516 in combination with siRNA directed against bacterial luciferase or ANGPTL4, respectively. Cells were lysed after siRNA washout and incubation with fresh GW501516-containing medium for 16 h. RNA was quantified by real-time RT-PCR. Statistics: P < 0.0001; ANOVA; n = 3; *significantly different from control (post hoc P < 0.05). D: C2C12 LIPE expression after ANGPTL4 knockdown. Cells were treated as described above (see C). RNA was quantified by real-time RT-PCR. Statistics: P = 0.0063; ANOVA; n = 3; *significantly different from DMSO (post hoc P < 0.05); **significantly different from GW501516 + control siRNA (post hoc P < 0.05).
###end p 58
###begin p 59
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 498 499 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 501 502 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 508 509 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 546 553 546 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANGPTL4</italic>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 594 595 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 672 673 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 855 856 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 888 889 888 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 48 54 <span type="species:ncbi:9606">humans</span>
###xml 80 85 <span type="species:ncbi:9606">human</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
###xml 823 828 <span type="species:ncbi:9606">human</span>
Association of ANGPTL4 with lipid metabolism in humans. A and B: Association of human plasma ANGPTL4 with fasting NEFA (A) and WAT lipolysis (B). Plasma ANGPTL4 and NEFA were determined in 108 subjects. A: Fasting plasma NEFAs were adjusted for sex, age, and BMI. B: As an estimate of WAT lipolysis, the area under the curve (AUC) of NEFA during OGTT was used and adjusted for sex, age, BMI, and the AUC of insulin during OGTT. Adjustments were achieved by multivariate linear regression modeling. C, D, and E: Association of basal human myotube ANGPTL4 expression with basal PPARD expression (C), WAT lipolysis of the donors (D), and plasma ANGPTL4 levels of the donors (E). RNA was quantified by real-time RT-PCR (relative arbitrary units [RAU]). Glycerol and ANGPTL4 levels were measured in plasma. Data derived from 38 human donors are plotted. C and E: Unadjusted data are shown. In D, as an estimate of WAT lipolysis, the AUC of glycerol during OGTT was used and adjusted for sex, age, BMI, and the AUC of insulin during OGTT. Adjustments were achieved by multivariate linear regression modeling.
###end p 59
###begin p 60
###xml 116 121 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPARD</italic>
###xml 707 711 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIPE</italic>
Hypothetical model of mANGPTL4's role in lipid metabolism. In states of increased muscle PPAR-delta activity and/or PPARD expression, such as fasting and exercise, SKM produces and secretes ANGPTL4. Simultaneously, muscular fatty acid oxidation is increased by PPAR-delta-dependent induction of beta-oxidative enzymes. Via the circulation, mANGPTL4 enhances WAT lipolysis and thus prevents too strong decrements of plasma NEFA levels and ensures ongoing fuel supply of the stressed (fasting or working) muscle. Together with ANGPTL4's inhibitory effect on LPL, this mechanism is expected to provoke loss of WAT mass. Furthermore, as derived from our in vitro data, ANGPTL4 could stimulate SKM lipolysis via LIPE induction in an autocrine/paracrine manner. This effect would constitute, in addition to PPAR-delta's inductive effect on beta-oxidation, a synergistic mode of PPAR-delta action on muscle lipid catabolism (IMCL, intramyocellular lipids).
###end p 60
###begin p 61
###xml 49 54 <span type="species:ncbi:9606">human</span>
Genes induced by both palmitate and linoleate in human myotubes
###end p 61
###begin p 62
Cells were treated for 20 h with 1.25% BSA for control or 0.5 mmol/l LCFA (changes >/=2-fold, LCFA vs. BSA).
###end p 62

